Skip to main content
. 2013 Apr 3;2013:236963. doi: 10.1155/2013/236963

Figure 3.

Figure 3

Adverse events of rifaximin versus nonabsorbable disaccharides in the treatment of hepatic encephalopathy. M-H: Mantel Haenszel.